Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomised placebo-controlled PROTOSTAR study
Br J Dermatol 2025;192:618–628 doi: 10.1093/bjd/ljae502
Prajapati et al. conducted the PROTOSTAR trial to assess guselkumab in paediatric patients with moderate-to-severe plaque psoriasis. Guselkumab significantly improved skin clearance versus placebo at Wk16, with high response rates sustained through Wk52 and a favourable safety profile.
This multicentre phase III study enrolled children aged ≥6 to <18 years and compared guselkumab against placebo and an active reference (etanercept) over a 52-week period. Key efficacy endpoints included IGA0/1 and PASI75/90/100, assessed at Wk16. Safety and patient-reported quality-of-life outcomes were also evaluated throughout.
Keywords:
